NEONC TECHNOLOGIES FILES 8-K: REG FD & EXHIBITS

Ticker: NTHI · Form: 8-K · Filed: Sep 11, 2025 · CIK: 1979414

Sentiment: neutral

Topics: disclosure, financials, regulatory

TL;DR

NEONC TECHNOLOGIES FILED AN 8-K ON 9/10/25 FOR REG FD AND EXHIBITS.

AI Summary

On September 10, 2025, NEONC TECHNOLOGIES HOLDINGS, INC. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporated in Delaware with its principal executive offices in Calabasas, CA, operates in the Pharmaceutical Preparations sector.

Why It Matters

This 8-K filing provides important updates on regulatory disclosures and financial exhibits for NEONC TECHNOLOGIES HOLDINGS, INC., which could impact investor understanding of the company's current status.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating immediate operational or financial distress.

Key Numbers

Key Players & Entities

FAQ

What specific information is being disclosed under Regulation FD?

The filing indicates a 'Regulation FD Disclosure' but does not detail the specific information in the provided text.

What financial statements or exhibits are included in this filing?

The filing lists 'Financial Statements and Exhibits' as an item, but the specific contents are not detailed in the provided text.

When was NEONC TECHNOLOGIES HOLDINGS, INC. incorporated?

The company was incorporated in Delaware, as stated in the filing.

What is the primary business sector for NEONC TECHNOLOGIES HOLDINGS, INC.?

The company's Standard Industrial Classification is 2834, which corresponds to Pharmaceutical Preparations.

What is the principal executive office address for the company?

The principal executive offices are located at 23975 Park Sorrento, Suite 205, Calabasas, CA 91302.

Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-09-11 17:00:29

Key Financial Figures

Filing Documents

01

Item 7.01. Regulation FD Disclosure. On September 10, 2025, NeOnc Technologies Holdings, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has authorized the Company to proceed with Phase IIa/IIb of its NEO212-01 clinical trial. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 furnished hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated September 10, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 11, 2025 NeOnc Technologies Holdings, Inc. By: /s/ Amir Heshmatpour Name: Amir Heshmatpour Title: President and Executive Chairman 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing